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Buruli Ulcer in 
Gabon, 2001–2010
To the Editor: Worldwide, 
Buruli ulcer is the third most common 
mycobacterial infection, following 
only tuberculosis and leprosy (1,2). 
It has been identiﬁ  ed in 30 countries, 
including 12 African countries (1–3). 
For Gabon, the ﬁ  rst report of a case 
consistent with Buruli ulcer was 
published in 1961 (4). The patient was 
a European woman who sought care at 
a hospital in Lambaréné for a painless 
upper arm nodule, which evolved into 
a plaque and then an extensive ulcer. 
The only other Buruli ulcer reports 
available for Gabon are a case report 
from 1968 and a case-series report 
from 1986 (5,6). We report data for 
Buruli ulcer in this sub-Saharan 
African country for 2001–2010, 
including prevalence within a hospital 
population and clinical presentation of 
the cases. These data can be used to 
assess long-term developments in the 
number of cases of Buruli ulcer in this 
region.
In Gabon, the major focus 
of Buruli ulcer is the area around 
Lambaréné (population ≈25,000), the 
capital of Moyen Ogooué Province 
(population  ≈35,000). It is located 
near the equator in the central African 
rainforest. Lambaréné lies near the 
conﬂ  uence of 2 major rivers, Ogooué 
and Ngounié, and is the starting point 
for one of the largest river deltas in 
Africa. Numerous lakes are present 
throughout the region.
The Albert Schweitzer Hospital 
in Lambaréné serves the entire 
province. At this hospital, Buruli ulcer 
is diagnosed on the basis of clinical 
presentation. In addition, tissue 
samples are sent to the Prince Leopold 
Institute of Tropical Medicine in 
Belgium for PCR analysis. All cases 
are treated surgically, and since 2006, 
patients have received rifampin and 
streptomycin as well. Since 2007, 
patient information has been recorded 
on a BU-02 form, designed by the 
World Health Organization to register 
and report cases of Buruli ulcer (1). 
We reviewed cases of Buruli ulcer 
at the Albert Schweitzer Hospital. 
We checked the hospital registry and 
patient records from 2001 through 
2010 to identify probable cases of 
Buruli ulcer on the basis of clinical 
appearance and response to treatment. 
We also gathered information from 
BU-02 forms from 2007 through 
2010.
During 2001–2010, the number 
of patients admitted to surgical wards 
because of suspected Buruli ulcer 
ranged from 5 to 40 per year (average 
25 patients/year) (Figure). Despite 
moderate variability from year to year, 
the number of cases over the years 
increased (χ2 for trend, p = 0.003), 
which could be associated with 
increased awareness of the disease. 
The variability was not caused by 
changes in the number of patients 
hospitalized.
During 2007–2010, detailed 
clinical information from BU-02 
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Figure. Number (line) and prevalence (in parentheses) of Buruli ulcer cases, Gabon, 2001–
2010. LETTERS
forms was available for 77 patients. 
PCR results were available for 57 
patients and conﬁ  rmed the diagnosis 
for 39. Patient ages ranged from 2 to 
72 years; 40 (52%) patients were <15 
years of age. The male/female ratio 
was 0.83. For 44 (57%) of the patients, 
Buruli ulcer was a new diagnosis. In 
addition, 56 (73%) patients had an 
ulcerative lesion, and 21 (37%) of 
these had lesions >5 cm. The lesions 
were located on the lower arm for 
41 (53%) patients, upper arm for 28 
(36%) patients, chest and/or back for 
7 (9%) patients, and perineal region 
for 1 (1%) patient. 
Depending on the type of lesion, 
the length of hospitalization ranged 
from 1 to 352 days (median 31 days). 
The longest hospitalization was almost 
1 year; the patient was a child who had 
severe lesions and lived in conditions 
in which adequate wound care and 
follow-up after hospital discharge 
were unlikely.
In Gabon, the available data on 
Buruli ulcer come mainly from surgical 
wards in areas where prevalence is 
high. A national survey of hospital 
registration data in 2005 detected 3 
cases in Ngounie Province in southern 
Gabon and 5 cases in Woleu-Ntem 
Province in northern Gabon. All cases 
are thought to have been acquired 
locally, thus establishing the existence 
of 2 previously unknown foci (U. 
Ateba Ngoa et al., unpub. data).
Buruli ulcer has a strong 
economic effect on the community 
and health facilities. For example, in 
2010, management of the disease at 
the Albert Schweitzer Hospital cost an 
estimated 554–1,660 euros per person, 
not including drug costs (7). In 2009, 
African countries where Buruli ulcer is 
endemic, including Gabon, signed the 
Cotonou Declaration (8). According to 
this declaration, these countries have 
committed themselves to ﬁ  ght Buruli 
ulcer by several measures, including 
assessing the magnitude of the disease 
and conducting surveillance. 
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Ebola Virus 
Antibodies in 
Fruit Bats, Ghana, 
West Africa
To the Editor: Fruit bats are the 
presumptive reservoir hosts of Ebola 
viruses (EBOVs) (genus Ebolavirus, 
family Filoviridae). When transmitted 
to humans and nonhuman primates, 
EBOVs can cause hemorrhagic fevers 
with high case-fatality rates.  In 2008, 
we detected Zaire EBOV (ZEBOV) 
antibodies in a single migratory fruit 
bat (Eidolon helvum) from a roost in 
Accra, Ghana (1). This bat is common 
in sub-Saharan Africa and lives in 
large colonies, often in cities. The 
ﬂ  ight of an individual E. helvum bat 
during migration has been recorded as 
>2,500 km (2). 
To understand whether the single 
seropositive Eidolon helvum bat was 
evidence of EBOV circulation in the 
Greater Accra Region or elsewhere in 
sub-Saharan Africa, we tested serum 
of 88 nonmigratory fruit bats from 
the surrounding region of Ghana. 
Serum samples had been collected, 
as previously described (3,4), 
during May–June 2007 from fruit 
bats in woodland and tropical forest 
habitats in southern Ghana within 
180 km of Accra. Initial screening 
for EBOV antibodies was conducted 
by using ELISA with a 1:1 mixture 
of recombinant nucleoprotein (NP) 
of ZEBOV and Reston EBOV 
(REBOV). Proteins were expressed 
in an Escherichia coli expression 
vector with a polyhistadine tag (1,5). 
Samples with optical density (OD) 
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